Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Xinnong Chemical Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, MCKOY, QUINCY ANDRE, who is also the busiest examiner for the portfolio with 1 pending office action. The prosecution is currently limited to 1 distinct art unit.
The concentration of the entire active portfolio under 1 distinct examiner suggests a very narrow technical focus for the company's current filings. This allows practitioners to tailor their arguments specifically to the preferences and examination style of MCKOY, QUINCY ANDRE. The lack of multiple active cases simplifies the coordination required to maintain consistency across the portfolio.
Operating within a single art unit provides a stable environment for patent prosecution. The company can expect the application of a uniform set of examination standards and prior art interpretations. This focused approach reduces the complexity of managing the company's intellectual property interests at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18857320 | Cryptolepine Salt Derivative, Preparation Method, and Use Thereof | MCKOY, QUINCY ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18857320 | Cryptolepine Salt Derivative, Preparation Method, and Use Thereof | MCKOY, QUINCY ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857320 | Cryptolepine Salt Derivative, Preparation Method, and Use Thereof | MCKOY, QUINCY ANDRE | 1626 | §102§112 | Non-Final OA | — | Pending | Oct 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Xinnong Chemical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quincy Andre Mckoy has the most, with 1 of Zhejiang Xinnong Chemical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.